SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel $INTC is trending as chatter swirls around a potential investment from Apple $AAPL as part of Intel's turnaround efforts, fueled by a recent Bloomberg report. Community members are speculating about the implications of Apple taking a stake and potential collaborations, while some express skepticism, recalling past struggles. The news arrives amid broader discussions of government support for US chip manufacturing and Intel's role in the AI landscape.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a surge in investor interest, fueled by a recent Air Force contract and non-dilutive funding, which validates the company's quantum computing roadmap. The community is actively discussing the stock's potential, comparing it to other high-growth tech stocks and debating whether it's overvalued. Some traders are pointing to a potential short squeeze, while others highlight the long-term potential of quantum computing and the company's partnerships.

Lithium Americas Corp. engages in the development of the Thacker Pass project. It is focused on advancing Thacker Pass to production it is located in northern Nevada. The company was founded on January 23, 2023 and is headquartered in Vancouver, Canada.

Lithium Americas Corp (NewCo)

Lithium Americas Corp

Lithium Americas ($LAC) is trending due to reports of the Trump administration potentially taking an equity stake in the company linked to a $2.26 billion Energy Department loan, sparking significant community discussion around potential government backing and the future of lithium supply. The news has triggered a surge in the stock price as investors speculate on the implications for the company's Thacker Pass project and the broader lithium sector, with some comparing it to previous government investments in critical industries. Discussions also include potential dilution and off-take agreements.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending following positive Phase I/II data for its Huntington's disease gene therapy, with analysts raising price targets and the community discussing its potential for accelerated FDA approval. Bullish sentiment is fueled by the statistically significant slowing of disease progression, while some traders are wary of a potential offering or pullback. The stock's high short interest is adding to the volatility as traders debate whether to short the stock or ride the momentum.

TNF Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

TNF Pharmaceuticals Inc.

TNF Pharmaceuticals (TNFA) is trending as traders discuss its recent strategic shift towards quantum computing and a name change to Q/C Technologies, sparking both excitement and skepticism. Bullish sentiment centers on the potential of their exclusive rights to light-speed laser processing for cryptocurrency applications, while bears cite concerns about dilution and the company's history. The community is actively debating whether this pivot justifies the stock's increased volatility and potential for a short squeeze.

Astera Labs, Inc. is a global semiconductor company, which engages in the provision of hardware and software solutions for AI and cloud infrastructure applications to solve data, memory, and networking bottlenecks. It operates through the following geographical segments: Taiwan, China, United States, and Other. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

ALAB is trending due to a significant sell-off, with community members citing potential Intel/Nvidia competition and overvaluation concerns as possible catalysts; some suspect market manipulation. Despite strong YTD growth fueled by PCIe demand and a recent positive earnings report, investors are debating its sustainability amid competition from major players like AVGO and MRVL. Discussions include whether the drop is a buying opportunity or a sign of further declines.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending amid speculation about a potential buyout or partnership, especially with other companies in the weight loss space being acquired. Community members are actively discussing potential suitors and the value of Viking's pipeline, citing positive trial data and a manageable tolerability profile. Some traders are eyeing technical indicators, while others are focused on upcoming presentations and potential catalysts.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending amid debates about its valuation and future prospects, with discussions focusing on its lack of current revenue and potential for an offering. Community sentiment is divided, with some highlighting insider selling and regulatory hurdles, while others point to the company's potential role in powering AI data centers. The stock's significant gains over the past month have also spurred conversations around pullbacks and potential buying opportunities within the nuclear sector.

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Immuneering Corp - Ordinary Shares Class A

IMRX is trending due to positive survival data in its Phase 2a trial for pancreatic cancer treatment, sparking community interest and analyst upgrades. However, a proposed public offering is creating mixed sentiment, with some fearing dilution while others see it as a strategic move. The community is actively discussing the balance between the promising data and the potential impact of the offering on the stock's future.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as the community discusses its recent price movement and potential breakout above the $15-$16 resistance level, with some pointing to a shift in market sentiment. The groundbreaking of the Georgia plant is also generating buzz, although some express concerns about cash burn and production timelines. Overall, the conversation is focused on whether Rivian can maintain its upward momentum and capitalize on upcoming catalysts like the R2 launch.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aslan Pharmaceuticals Begins Voluntary Liquidation

Aslan Pharmaceuticals (ASLN) has released an update. Aslan Pharmaceuticals has initiated voluntary liquidation for its main operating subsidiary af...

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) Short Interest Update

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN  Get Free Report) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 290,500...

Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders

SAN MATEO, Calif. and SINGAPORE, March 27, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceutical (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...

Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Urogen Pharma (URGN) and Legend Biotech (LEGN)

Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aslan Pharmaceuticals (ASLN Research Report), Urogen Pharma...

Aslan Pharmaceuticals price target lowered by $8 at H.C. Wainwright, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Aslan Pharmaceuticals price target lowered by $5 at Piper Sandler, here's why

Aslan Pharmaceuticals announces $5M registered direct offering

ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering

SAN MATEO, Calif. and SINGAPORE, March 12, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative...

ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

TREK-DX, the first randomized, double-blind, placebo-controlled study to be conducted in a dupilumab-experienced atopic dermatitis (AD) patient population, has started enrolling patients in the US...

ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors

New translational data from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD shows eblasakimab performed better than dupilumab in improving airway function and...

Aslan Pharmaceuticals Ltd. is a clinical-stage immunology biopharmaceutical company, which develops novel therapeutics. It focuses on atopic dermatitis, other immunology indications and autoimmune disease. Its pipeline includes ASLAN003 and Eblasakimab. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.

ASLAN Pharmaceuticals Ltd - ADR

Will Costco Wholesale ($COST) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

ASLN
ASLAN Pharmaceuticals

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ASLN News

ASLN ASLAN Pharmaceuticals